VivoSeq
Other

Dendritic Cell

0

Pipeline Programs↗

5

Active Trials↗

1

Companies Involved↗

Dendritic Cell is an early-stage landscape with 0 programs across 1 company. The most active players are Argos Therapeutics.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

67/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Argos Therapeutics

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

55

clinical trials

Completed29 · 53%
Terminated10 · 18%
Unknown status7 · 13%
Withdrawn4 · 7%
Recruiting3 · 5%
Active, not recruiting2 · 4%

Clinical Trials

Trial Activity

55 trials

A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.
Recruiting·IIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS·Phase 2·NCT04166006·51 enrolled
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT05325632·53 enrolled
A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)
Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT05809752·18 enrolled
Allogeneic Regulatory Dendritic Cell (DCreg) Renal Study
Active, not recruiting·—·Phase 1·NCT03726307·28 enrolled
First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients
Active, not recruiting·UUniversity Hospital, Antwerp·Phase 1/2·NCT05964361·10 enrolled
Tumor RNA Transfected Dendritic Cell Vaccines
Completed·US Department of Veterans Affairs·Phase 1·NCT00108264
Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma
Completed·YYale University·Phase 1·NCT00698776·6 enrolled
Autologous Dendritic Cells Pulsed With Autologous Apoptotic Tumor Cells Administered to Patients With Brain Tumors
Completed·RRockefeller University·Phase 1·NCT00893945·19 enrolled
Vaccination With Autologous Dendritic Cells Pulsed With HIV-Antigens for Treatment of Patients With Chronic HIV-Infection
Completed·SStatens Serum Institut·Phase 1·NCT00856154·12 enrolled
Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor
Completed·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT01171469·8 enrolled
Tumor Lysate Pulsed Dendritic Cell Immunotherapy for Patients With Brain Tumors
Completed·—·Phase 2·NCT00576537·50 enrolled
Comparison of Dendritic Cell-Based Therapeutic Vaccine Strategies for HIV Functional Cure
Completed·—·Phase 1·NCT03758625·40 enrolled
Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma
Completed·UUniversity Hospital Carl Gustav Carus·Phase 1·NCT00988312·9 enrolled
Autologous Dendritic Cell Vaccine in HIV1 Infection
Completed·—·Phase 1/2·NCT00510497·11 enrolled
Safety and Immunogenicity of a Vaccine Dendritic Cell-based Pulsed With Autologous Heat-inactivated in HIV-1 Infected Patients
Completed·—·Phase 1·NCT02767193·36 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)